VIDEO: 4D-150 shows positive interim results in phase 2 trial for severe wet AMD

Issue: March 25, 2024

ByArshad Khanani, MD, MA, FASRS

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Arshad M. Khanani, MD, MA, FASRS, overviews phase 2 efficacy and safety data for 4D-150 for the treatment of neovascular age-related macular degeneration.

Compared with those treated with aflibercept, patients treated with 4D-150 (4D Molecular Therapeutics) demonstrated stable visual acuity though week 24 and minimal to no fluctuations in central subfield thickness, according to Khanani. In addition, the 4D-150 cohort saw a significant reduction in treatment burden overall.

“In this trial, 4D-150 was found to be safe and well tolerated through week 24 in these patients with severe disease,” he said.

Published by:

Sources/Disclosures

Collapse

Source:

Khanani AM. First interim results (24 weeks) for the randomized phase 2 dose expansion stage of the PRISM clinical trial of 4D-150 in high need patients with nAMD. Presented at: Angiogenesis, Exudation, and Degeneration 2024; Feb. 3, 2024 (virtual meeting).

Disclosures: Khanani reports consulting for and receiving research funding from 4DMT.

Angiogenesis, Exudation and Degeneration Meeting

Read more

VIDEO: 4D-150 shows positive interim results in phase 2 trial for severe wet AMD

Related Content